Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial
| Autor: | John E A, Blair, Cezar, Macarie, Witold, Ruzyllo, Antonella, Bacchieri, Giovanni, Valentini, Maria, Bianchetti, Peter S, Pang, Matthew E, Harinstein, Hani N, Sabbah, Gerasimos S, Filippatos, Mihai, Gheorghiade, John, Nanas |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Inotrope
Adult Male medicine.medical_specialty Cardiotonic Agents Adolescent Hemodynamics Blood Pressure Kidney Function Tests Ventricular Dysfunction Left Double-Blind Method Heart Rate Internal medicine Heart rate Etiocholanolone medicine Humans Pharmacology (medical) Pulmonary wedge pressure Aged Pharmacology Aged 80 and over Heart Failure Ejection fraction Dose-Response Relationship Drug business.industry General Medicine Middle Aged medicine.disease Blood pressure Istaroxime Echocardiography Anesthesia Heart failure Cardiology Female business |
| Zdroj: | American journal of therapeutics. 15(3) |
| ISSN: | 1536-3686 |
| Popis: | BACKGROUND Current inotropes have inodilator properties and, although are frequently used in acute heart failure syndromes, do not improve outcomes, likely from reduction in systolic blood pressure and increasing in arrhythmias, causing worsened myocardial ischemia and end-organ damage. Istaroxime is a novel agent that, in animal models, has both inotropic (inhibition of the Na/K ATPase channel) and lusitropic (stimulation of sarcoplasmic reticulum calcium ATPase activity) effects. HORIZON-HF is designed to test the hypothesis that istaroxime is effective in improving central hemodynamics and left ventricular (LV) function, without lowering systolic blood pressure, increasing heart rate, and worsening renal function or myocardial necrosis. METHODS AND RESULTS This was a phase 2, randomized, double-blind, placebo-controlled, multicenter dose escalation exploratory study comparing 3 different doses of istaroxime to placebo in patients with LV systolic dysfunction (LV ejection fraction |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|